- Fluor ( NYSE: FLR ) has been selected to perform procurement and construction management for a large-scale biologics drug substance manufacturing facility located in Scandinavia.
- The project is being led by Fluor’s ( FLR ) Advanced Technologies & Life Sciences business, with construction underway.
- Scheduled to be operational by 2025, the facility will produce new capacity for advanced biologics that are used in a variety of treatments including vaccines, oncology and quality-of-life medicines.
- FLR shares were down over 1% premarket
For further details see:
Fluor leads biologics manufacturing facility expansion in Scandinavia